FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.
What happened
FDA inspected the Alembic Research Centre in Vadodara, Gujarat, India, from March 3 to 7, 2025, as part of its Bioresearch Monitoring Program, reviewing a clinical in vivo bioequivalence study of an investigational drug. The agency found that the 'Nature and Purpose of this Study' section of the informed consent form said the study was a clinical research project 'but no part of it is of an experimental nature.' The company responded on March 26, 2025, but FDA called the response inadequate because it lacked details on how the investigator would comply with consent rules and did not include the revised consent forms with Ethics Committee approval.
What FDA found
The consent form told subjects that no part of the study was experimental, which could mislead them about what they were agreeing to.
21 CFR 312.60 and 21 CFR 50.20The consent form did not clearly describe the experimental nature of the study, which the basic elements of informed consent require.
21 CFR 50.25(a)(1)
What FDA wants
Within 15 business days, the investigator must write to FDA describing actions taken to prevent similar violations, including how he will ensure compliance with the informed consent rules. FDA also asked for the revised consent forms with Ethics Committee approval for all ongoing and planned studies, which the earlier response did not include.
Who should pay attention
- clinical investigators running bioequivalence studies
- sites and contract research organizations that draft consent forms
- drug sponsors that rely on this site's study data in applications
This is a summary. Read the original letter on fda.gov.